Penny stock picks | research with support and resistance for trading | stock investing
day investing picks penny stock trading
Skip Navigation Links
    Home
    •   About US
    Market Activity
    World Indices
    Market Watch
    Customer Service
    Learning Center
    Economic Event
    Login


Join Now




Advertise 2 my advertising 3 of 5
 

NEKTAR THERAPEUTICS COM support, resistance research

Stock : NKTR |   Stock Recommendations : Buy
Sector : Medical Equipment & Supplies |   First resistance : 7.26
Stock Name : NEKTAR THERAPEUTICS COM |   Second resistance : 13.15
Buy Near : 5.53 |   Third resistance : 17.00
StopLoss : 3.64 |   First Support : 3.64
Posted date : 11/2/2008 12:00:00 AM |   Second Support : 2.91


Nektar Therapeutics com (NKTR) given a nice double top breakout on 10/31/08 with good volume. Again many technical indicators also have given a buy signal, with

   rising moving average weekly and daily Stockhastic given a buy signal and ADX also given a buy signal. Nektar Therapeutics com (NKTR) reported positive Phase 1 data for its lead proprietary oncology product candidate, NKTR-102. As per technical indicator analysis this Stock looks good candidate for portfolio investment and also for day trading, Stock investing, trend trading | swing trading. Due to Stock market and economic condition keep tight stop loss on all position. Buy with our first target $7.26 and keep stop loss $3.64



Penny Stocks



Recent News Head Lines
Hedge Funds Aren’t Impressed By Nektar Therapeutics (NKTR)
(Wed, 24 Jun 2020 01:46:51 +0000)
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]
Edited Transcript of NKTR.OQ earnings conference call or presentation 7-May-20 9:00pm GMT
(Mon, 15 Jun 2020 01:25:45 +0000)
Q1 2020 Nektar Therapeutics Earnings Call
Why Is Nektar (NKTR) Up 12% Since Last Earnings Report?
(Sat, 06 Jun 2020 15:31:03 +0000)
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)
(Thu, 04 Jun 2020 21:00:00 +0000)
Nektar Therapeutics (NASDAQ:NKTR) today announced the presentation of results from the Phase 1b study evaluating multiple ascending doses of NKTR-358, a first-in-class T regulatory cell stimulator, which is being developed as a potential therapeutic for a range of autoimmune disorders, including systemic lupus erythematosus (SLE).
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology (EULAR 2020)
(Fri, 29 May 2020 21:00:00 +0000)
Nektar Therapeutics (NASDAQ: NKTR) announced today that it will webcast an analyst and investor conference call on Friday, June 5, 2020 at 11:00 a.m. EDT during EULAR 2020. The event will follow Thursday's virtual poster presentation of the data from a Phase 1b multiple ascending dose study of NKTR-358, a first-in-class investigational regulatory T cell stimulator, in patients with systemic lupus erythematosus.


Never go against major trend for Penny stock trading | investing
  


Home for ۩ Day Trading | Breakout Stock trading system | Penny Stock Investing | Market Research

Contact Us | Affiliate | Disclaimer | Feedback | Help | Site Map | RSS  RSS
All Rights Reserved © 2000-2006 Flyingstock.com
Chart courtesy of StockCharts.com
Penny stock trading- NEKTAR THERAPEUTICS COM for penny stock investing Day Trading

This Service is solely an information service provided by the automated software tool & is for entertainment purposes only. It should be understood that there is no guarantee that past performance of our stock trading system or day trading Strategy or Penny stock picks will be indicative of future results.